Detail akcie Avacta Grp online

Business Summary: Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Avacta Group Plc revenues remained flat at L56K. Net loss applicable to common stockholders excluding extraordinary items increased from L5.7M to L16.1M. Revenues reflect market conditions. Higher net loss reflects Therapeutics segment loss increase of 2% to L9.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -L0.02 to -L0.04.